Browse
Publications
Preprints
About
About UCL Open: Env.
Aims and Scope
Editorial Board
Indexing
APCs
How to cite
Publishing policies
Editorial policy
Peer review policy
Equality, Diversity & Inclusion
About UCL Press
Contact us
For authors
Information for authors
How it works
Benefits of publishing with us
Submit
How to submit
Preparing your manuscript
Article types
Open Data
ORCID
APCs
Contributor agreement
For reviewers
Information for reviewers
Review process
How to peer review
Peer review policy
My ScienceOpen
Sign in
Register
Dashboard
Search
Browse
Publications
Preprints
About
About UCL Open: Env.
Aims and Scope
Editorial Board
Indexing
APCs
How to cite
Publishing policies
Editorial policy
Peer review policy
Equality, Diversity & Inclusion
About UCL Press
Contact us
For authors
Information for authors
How it works
Benefits of publishing with us
Submit
How to submit
Preparing your manuscript
Article types
Open Data
ORCID
APCs
Contributor agreement
For reviewers
Information for reviewers
Review process
How to peer review
Peer review policy
My ScienceOpen
Sign in
Register
Dashboard
Search
6
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,245
similar
All similar
Record
: found
Abstract
: not found
Book
: not found
Fachinformation Rebif (Stand: 09/2019)
Author(s):
Publication date:
2019
Read this book at
Bookmark
There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
UCL: UN SDG 09 Industry, Innovation, and Infrastructure
Data availability:
Comments
Comment on this book
Sign in to comment
Similar content
2,245
Rebif (interferon beta-1a), prescribing information
Authors:
PND2 SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY: 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Authors:
J Simsarian
,
A. AL-Sabbagh
,
R. Bennett
…
Fachinformation Piperacillin-Tazobactam-Teva® 4 g/ 0,5 g Pulver zur Herstellung einer Infusionslösung 2017
Authors:
See all similar
Cited by
1
Krankheitsmodifizierende Therapie der sekundär progredienten Multiplen Sklerose
Translated title: Disease-modifying treatment of secondary progressive multiple sclerosis
Authors:
Olaf Hoffmann
,
Ralf Gold
See all cited by